Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Enspryng1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
2SATRALIZUMAB
(Enspryng (TN))		1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬3件: 11, 13, 86 💬
3Satralizumab (120 mg/PFS with NSD)
(Enspryng (TN))		1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
4Satralizumab (120 mg/vial)
(Enspryng (TN))		1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
5Satralizumab (120mg/vial)
(Enspryng (TN))		1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
6Satralizumab (Genetical Recombination)
(Enspryng (TN))		1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 86 💬
7Satralizumab (r-INN)
(Enspryng (TN))		1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
8Satralizumab (RO5333787/Enspryng /SA237)1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
9Satralizumab (RO5333787/Enspryng/SA237)1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
10Satralizumab (RO5333787/SA237)
(Enspryng (TN))		1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
11Satralizumab 120 mg
(Enspryng (TN))		1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
12Satrazlizumab (RO5333787/ Enspryng /SA237)1件: Satralizumab (Enspryng)1件: Satralizumab (Enspryng (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬